Ascletis Pharma Inc Asset Resilience Ratio

Latest as of December 2025: 22.13%

Ascletis Pharma Inc asset resilience ratio. Ascletis Pharma Inc (2VJ) has an Asset Resilience Ratio of 22.13% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 2VJ cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€457.36 Million

≈ $534.70 Million USD Cash + Short-term Investments

Total Assets

€2.07 Billion

≈ $2.42 Billion USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio of Ascletis Pharma Inc (2016–2025)

Asset resilience ratio of Ascletis Pharma Inc from 2016 to 2025. This chart shows how Ascletis Pharma Inc's Asset Resilience Ratio has changed over time. Read Ascletis Pharma Inc (2VJ) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Ascletis Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Ascletis Pharma Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€457.36 Million	22.13%
Total Liquid Assets	€457.36 Million	22.13%

Asset Resilience Insights

Good Liquidity Position: Ascletis Pharma Inc maintains a healthy 22.13% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Ascletis Pharma Inc Industry Peers by Asset Resilience Ratio

Compare Ascletis Pharma Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	36.07%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
3SBio Inc F:83B	Biotechnology	10.64%

Ascletis Pharma Inc Asset Resilience Ratio by Year (2016–2025)

Ascletis Pharma Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Ascletis Pharma Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	22.13%	€457.36 Million ≈ $534.70 Million	€2.07 Billion ≈ $2.42 Billion	-28.79pp
2024-12-31	50.92%	€1.08 Billion ≈ $1.26 Billion	€2.12 Billion ≈ $2.48 Billion	-28.14pp
2023-12-31	79.06%	€1.97 Billion ≈ $2.30 Billion	€2.49 Billion ≈ $2.91 Billion	+78.63pp
2022-12-31	0.42%	€11.20 Million ≈ $13.09 Million	€2.66 Billion ≈ $3.11 Billion	+0.24pp
2021-12-31	0.18%	€5.20 Million ≈ $6.08 Million	€2.83 Billion ≈ $3.31 Billion	-14.33pp
2017-12-31	14.51%	€143.83 Million ≈ $168.15 Million	€991.25 Million ≈ $1.16 Billion	+13.46pp
2016-12-31	1.05%	€5.61 Million ≈ $6.56 Million	€536.26 Million ≈ $626.95 Million	--

pp = percentage points

About Ascletis Pharma Inc

F:2VJ Germany Biotechnology

Market Cap

$623.07 Million

€532.95 Million EUR

Market Cap Rank

#10794 Global

#1268 in Germany

Share Price

€0.51

Change (1 day)

-6.48%

52-Week Range

€0.47 - €1.99

All Time High

€1.99